Zhenfan Yang

2.8k total citations · 1 hit paper
39 papers, 1.8k citations indexed

About

Zhenfan Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Zhenfan Yang has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Zhenfan Yang's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (11 papers) and Brain Metastases and Treatment (8 papers). Zhenfan Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (11 papers) and Brain Metastases and Treatment (8 papers). Zhenfan Yang collaborates with scholars based in China, United States and South Korea. Zhenfan Yang's co-authors include James Chih‐Hsin Yang, Dong‐Wan Kim, John Wong, Cecilia Lau, Wun‐Ching Yu, Irene Oi‐Lin Ng, Ronnie Tung‐Ping Poon, Darren A.E. Cross, Angela Jordan and Katarina Varnäs and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Zhenfan Yang

39 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

2016 523 citations Peter Ballard, James Yates et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhenfan Yang China	19	1.2k	1.1k	549	308	157	39	1.8k
Dana T. Aftab United States	20	574 0.5×	882 0.8×	803 1.5×	417 1.4×	202 1.3×	45	1.8k
Thanyanan Reungwetwattana Thailand	21	1.4k 1.1×	1.1k 1.1×	571 1.0×	321 1.0×	44 0.3×	72	1.9k
Soji Kakiuchi Japan	21	910 0.7×	850 0.8×	998 1.8×	313 1.0×	132 0.8×	41	1.9k
Rosa Caputo Italy	20	906 0.7×	1.3k 1.3×	1.0k 1.9×	355 1.2×	81 0.5×	21	2.3k
Michèle Beau‐Faller France	22	1.6k 1.3×	1.3k 1.2×	758 1.4×	554 1.8×	84 0.5×	61	2.1k
Roberta Caputo Italy	13	664 0.5×	805 0.8×	612 1.1×	317 1.0×	48 0.3×	27	1.4k
V. A. Miller United States	18	1.0k 0.8×	1.2k 1.1×	529 1.0×	195 0.6×	37 0.2×	37	1.5k
S. Gail Eckhardt United States	14	470 0.4×	779 0.7×	686 1.2×	302 1.0×	102 0.6×	46	1.3k
Frauke Bentzien United States	10	522 0.4×	665 0.6×	821 1.5×	298 1.0×	372 2.4×	12	2.1k

Countries citing papers authored by Zhenfan Yang

Since Specialization

Citations

This map shows the geographic impact of Zhenfan Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenfan Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenfan Yang more than expected).

Fields of papers citing papers by Zhenfan Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenfan Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenfan Yang. The network helps show where Zhenfan Yang may publish in the future.

Co-authorship network of co-authors of Zhenfan Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenfan Yang. A scholar is included among the top collaborators of Zhenfan Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenfan Yang. Zhenfan Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Mengzhao, Yan Xu, Wu‐Chou Su, et al.. (2024). Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations. Lung Cancer. 199. 108053–108053. 4 indexed citations

Li, Man, et al.. (2023). Multi-Objective Negotiation Mechanism in Manufacturing Enterprise Supply Chain Based on Multi-Agent. Journal of Global Information Management. 31(1). 1–22. 6 indexed citations

Chen, Kan, Zhenfan Yang, Yue Zhou, et al.. (2023). Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants. Frontiers in Immunology. 14. 1127935–1127935. 5 indexed citations

Bai, Yu, et al.. (2022). Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist. Journal of Experimental & Clinical Cancer Research. 41(1). 302–302. 17 indexed citations

Kang, Jin‐Hyoung, Hua‐Jun Chen, Xu‐Chao Zhang, et al.. (2018). Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer. Thoracic Cancer. 9(9). 1093–1103. 17 indexed citations

Zhang, Qi, Xu‐Chao Zhang, Jin‐Ji Yang, et al.. (2018). EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib. Journal of Thoracic Oncology. 13(9). 1415–1421. 56 indexed citations

Wang, Nannan, Xiangjiao Meng, Jia Wang, et al.. (2018). Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer. Oncology Reports. 41(1). 77–86. 28 indexed citations

Ahn, Myung‐Ju, Dong‐Wan Kim, Byoung Chul Cho, et al.. (2017). Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. The Lancet Respiratory Medicine. 5(11). 891–902. 86 indexed citations

Kang, Jin‐Hyoung, Hua‐Jun Chen, Zheng Wang, et al.. (2017). Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. Journal of Thoracic Oncology. 13(4). e49–e53. 44 indexed citations

10.

Ballard, Peter, James Yates, Zhenfan Yang, et al.. (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical Cancer Research. 22(20). 5130–5140. 523 indexed citations breakdown →

11.

Zhao, Jing, Xin Ye, Yan Xu, et al.. (2016). EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. Cancer Chemotherapy and Pharmacology. 78(6). 1305–1310. 44 indexed citations

12.

Yang, James Chih‐Hsin, Dong‐Wan Kim, Sang‐We Kim, et al.. (2016). Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. Journal of Clinical Oncology. 34(15_suppl). 9002–9002. 78 indexed citations

13.

Ye, Xin, Zhongzheng Zhu, Lei Zhong, et al.. (2013). High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?. Journal of Thoracic Oncology. 8(9). 1118–1120. 65 indexed citations

14.

Ye, Xin, Zhongzheng Zhu, Lei Zhong, et al.. (2013). Abstract A36: High T790M detection rate in TKI-naïve NSCLC with EGFR sensitive mutation: Truth or artifact?.. Molecular Cancer Therapeutics. 12(11_Supplement). A36–A36. 1 indexed citations

15.

Yang, Zhenfan, et al.. (2007). Blockade of chemokine receptor CXCR4 for the treatment of hepatocellular carcinoma metastasis. Molecular Cancer Therapeutics. 6. 2 indexed citations

16.

Yang, Zhenfan, et al.. (2004). Linking Inflammation to Acute Rejection in Small-For-Size Liver Allografts: The Potential Role of Early Macrophage Activation. American Journal of Transplantation. 4(2). 196–209. 40 indexed citations

17.

Li, Zhong‐Guang, Wei Li, Zhenfan Yang, et al.. (2004). Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Therapy. 11(14). 1165–1169. 33 indexed citations

18.

Yang, Zhenfan, et al.. (2003). Long-term liver allograft survival induced by combined treatment with rAAV-hCTLA4Ig gene transfer and low-dose FK5061. Transplantation. 75(3). 303–308. 13 indexed citations

19.

Mathias, Carla J., et al.. (2002). Synthesis and evaluation of 99mTc(CO)3-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nuclear Medicine and Biology. 29(5). 569–573. 54 indexed citations

20.

Wang, Weilin, et al.. (2000). Intracerebral hemorrhage after liver transplantation. Liver Transplantation. 6(3). 345–348. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact